Feasibility & Characterization of Project: EVO Monitor Cognitive Measurements

Sponsor
Akili Interactive Labs, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT02792296
Collaborator
(none)
71
2
3
5
35.5
7.1

Study Details

Study Description

Brief Summary

This is an open-label study in adults to assess at-home Project: EVO Monitor measurements over repeat play cycles. The study has three arms:playing multiple times per day, once daily, and once weekly for 4 to 8 weeks.

Condition or Disease Intervention/Treatment Phase
  • Other: Project: EVO Monitor
N/A

Detailed Description

This is an open-label study in adults ages 40 to 55 to assess Project: EVO Monitor measurements over repeat play cycles. The study has three arms: adults playing multiple times per day, adults playing once daily, and adults playing once weekly. The investigators plan to evaluate 76 participants (N = 30 in the daily and weekly arms, and N=16 in the multiple times per day arm) in two sites over a 4 to 8 week study period. The study period includes 2 in-clinic sessions and scheduled, at-home game play of the short (less than 7 minutes) Project: EVO Monitor.

Study Design

Study Type:
Interventional
Actual Enrollment :
71 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Study to Assess the Feasibility of and to Characterize Project: EVO Monitor Cognitive Function Measurements When Played Daily, Weekly, or Multiple Times Per Day in Adults 40-55 Years Old
Study Start Date :
Jun 1, 2016
Actual Primary Completion Date :
Nov 1, 2016
Actual Study Completion Date :
Nov 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Daily measurement

This arm will be asked to use the Project: EVO Monitor once a day for four weeks..

Other: Project: EVO Monitor
Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.

Experimental: Multiple times per day measurement

This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.

Other: Project: EVO Monitor
Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.

Experimental: Weekly measurement

This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.

Other: Project: EVO Monitor
Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.

Outcome Measures

Primary Outcome Measures

  1. Feasibility of at-home use as measured by percent of completed assigned sessions [4 to 8 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age: 40-55 at the time of informed consent

  • Ability to follow written and verbal instructions (English).

  • Male and Female (Gender-matched).

  • Ability to comply with all the testing and requirements.

Exclusion Criteria:
  • Current, controlled (requiring a restricted medication) or uncontrolled, self-reported psychiatric diagnosis with significant symptoms such as post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention deficit disorder, autism spectrum disorder, or other symptomatic manifestations that in the opinion of the Investigator that may confound study data/assessments.

  • Current self-reported community diagnosis of cognitive ailments such as dementia, Alzheimer's disease, stroke, traumatic brain injury, or other diseases that in the opinion of the Investigator that may confound study data/assessments.

  • Current diagnosis of severe learning disorder, dyslexia, or dyscalculia.

  • Current subjective complaints of inattention or memory loss.

  • Current use of psychotropic medication, prescription or otherwise.

  • Currently undergoing psychotherapy, behavioral therapy, or occupational therapy.

  • Motor condition that prevents game playing, as observed by investigator.

  • Impaired visual acuity, as defined by difficulty reading the informed consent even with corrective lenses.

  • Recent history (within the past 6 months) of suspected substance abuse or dependence.

  • History of seizures (exclusive of febrile seizures), a tic disorder, significant tics, a current diagnosis of Tourette's Disorder.

  • Taken part in a clinical trial within 30 days prior to screening.

  • Diagnosis of color blindness.

  • Regular use of psychoactive drugs that in the opinion of the Investigator may confound study data/assessments

  • Any other medical condition that in the opinion of the investigator may confound study data/assessments.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Preferred Research Partners Little Rock Arkansas United States 72211
2 Clinical Trials of Texas San Antonio Texas United States 78229

Sponsors and Collaborators

  • Akili Interactive Labs, Inc.

Investigators

  • Study Director: Ted Riley, Promedica International

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Akili Interactive Labs, Inc.
ClinicalTrials.gov Identifier:
NCT02792296
Other Study ID Numbers:
  • Akili-026
First Posted:
Jun 7, 2016
Last Update Posted:
Nov 6, 2016
Last Verified:
Nov 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No

Study Results

No Results Posted as of Nov 6, 2016